Tag
Postacute discharge to inpatient rehabilitation facilities (IRF) after acute ischemic stroke (AIS) is associated with a reduced 1-year risk of major adverse cardiovascular events (MACE) compared to discharge to home or skilled nursing facil
EUROASPIRE VI exposes wide gaps between ESC prevention and cardiac rehabilitation recommendations and everyday care across Europe — especially in high-risk regions. This article distills core guideline recommendations, what’s new, and
Post-MI adherence to diverse healthy dietary patterns is consistently linked to reduced mortality and cardiovascular events, underscoring the importance of diet quality in secondary prevention among MI survivors.
This study reveals that risk factor associations for subsequent coronary heart disease (CHD) events are systematically attenuated due to index event bias, challenging their clinical interpretation in secondary prevention and emphasizing the
Achieving a ≥50% reduction in LDL-C from baseline independently reduces recurrent cardiovascular events post-ischemic stroke, suggesting that combining relative and absolute LDL-C targets improves long-term outcomes.
Inflammatory blood biomarkers consistently predict long-term recurrent stroke risk up to 10 years post-event, independent of traditional vascular risk factors, underscoring the potential for anti-inflammatory secondary prevention strategies
A secondary analysis of ABYSS shows that in stable post-MI patients with preserved ejection fraction, higher heart rate remains prognostic and β-blocker interruption increases heart rate by about 10–13 bpm while worsening outcomes across he
A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hou
The LAST-long randomized trial found that an 18-month coordinator-led multimodal intervention did not significantly prevent functional decline or dependency in patients with mild stroke compared to standard care, highlighting challenges in
A large meta-analysis shows colchicine can lower MI and stroke risk without raising serious adverse events, but GI side effects remain a concern.
Two cohort analyses suggest greater adherence to the EAT‑Lancet diet is linked with lower recurrent non‑fatal vascular events—notably stroke—and that education and sex modify long‑term cardioprotective benefits of this sustainable, plant‑fo
In 273,770 US patients with established ASCVD, rising lipoprotein(a) (nmol/L) was steadily associated with higher risk of recurrent events; the excess risk was partially blunted in those receiving high‑impact LDL‑lowering therapy, most nota
This meta-analysis of nearly 29,000 CAD patients shows clopidogrel monotherapy reduces major cardiovascular events more than aspirin without increasing major bleeding risk, supporting clopidogrel as preferred secondary prevention.
Recent evidence challenges the routine use of long-term beta-blockers after myocardial infarction in patients with preserved ejection fraction, highlighting comparable outcomes with or without therapy and raising safety and efficacy conside
A large meta-analysis in The Lancet demonstrates that clopidogrel reduces MACCE risk by 14% over aspirin in CAD secondary prevention, with comparable safety over 5.5 years.
